MSB 2.38% $1.23 mesoblast limited

REMESTEMCEL for All Cause ARDS

  1. 1,863 Posts.
    lightbulb Created with Sketch. 484
    I recently read an interesting argument against Remestemcel-l's use in COVID ARDS. It was hidden away 79 pages, 4697th comment in that thread and thought it should be shared for discussion.

    While the discontinuation of the COVID ARDS trial is a dissapointment, and I agree that the number of cases is dwindling away, there is a reason the FDA still guided towards another trial and a possible EUA.

    Despite all the "Warp Speed" treatments touted as eliminating the issues a lot of them upon further studies have shown to have little to no effect on COVID. One individual here claiming to be a doctor touted regularly prescribing one of these treatments.

    On top of that there are still COVID Ards related deaths. If you want to look beyond COVID, which is the end-game of this exercise there are still ALL-CAUSE ARDS deaths.
    This is the immediate potential of Remestemcel beyond SR GVHD in children which may be approved anytime between now and August. Not even mentioning other promising potentially off-label use.

    Just thought I would provide some balance to a hideously imbalanced post. Not financial advise, DYOR especially with items as complicated as this.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.23
Change
-0.030(2.38%)
Mkt cap ! $1.404B
Open High Low Value Volume
$1.26 $1.30 $1.22 $10.22M 8.142M

Buyers (Bids)

No. Vol. Price($)
2 11752 $1.23
 

Sellers (Offers)

Price($) Vol. No.
$1.23 67205 1
View Market Depth
Last trade - 16.10pm 29/05/2024 (20 minute delay) ?
Last
$1.23
  Change
-0.030 ( 3.67 %)
Open High Low Volume
$1.26 $1.29 $1.22 1670014
Last updated 15.59pm 29/05/2024 ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.